The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to ...

The 2024-2025 flu season was one of the most severe in almost a decade, according to the Centers for Disease Control and ...

On the campaign trail last October, President Trump promised to let his health secretary, Robert F. Kennedy Jr., “go wild on ...

If Paramount’s $30-per-share, all-cash bid worth $108 billion (including debt) for complete ownership of WBD succeeds, it’ll ...

Federal health officials are reviewing the safety of two injectable drugs used to protect babies and toddlers from the RSV ...

The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...

US advisers end universal newborn hepatitis B vaccination, sparking backlash from medical experts who warn the move will ...

Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...

Get all of the latest breaking local and international news stories as they happen, with up to the minute updates and analysis, from Ireland's National Broadcaster ...

More than 30 agents conducted a surprise raid of Sanofi’s headquarters in Paris on Tuesday morning as part of a tax fraud investigation, according to a report from French newspaper Le Monde. A ...